Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2006 Oct;61(10):854-62.
doi: 10.1136/thx.2006.063271. Epub 2006 Jul 14.

Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis

R G Barr  1 , J Bourbeau, C A Camargo, F S F Ram
Affiliations
Meta-Analysis

Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis

R G Barr et al. Thorax. 2006 Oct.

Erratum in

  • Thorax. 2007 Feb;62(2):191

Abstract

Background: A systematic review was undertaken to evaluate the efficacy of tiotropium, a long acting anticholinergic drug, on clinical events, symptom scales, pulmonary function, and adverse events in stable chronic obstructive pulmonary disease (COPD).

Methods: A systematic search was made of the Cochrane trials database, MEDLINE, EMBASE, CINAHL, and a hand search of 20 respiratory journals. Missing data were obtained from authors and the manufacturer. Randomised controlled trials of > or =12 weeks' duration comparing tiotropium with placebo, ipratropium bromide, or long acting beta2 agonists (LABA) were reviewed. Studies were pooled to yield odds ratios (OR) or weighted mean differences with 95% confidence intervals (CI).

Results: Nine trials (8002 patients) met the inclusion criteria. Tiotropium reduced the odds of a COPD exacerbation (OR 0.73; 95% CI 0.66 to 0.81) and related hospitalisation (OR 0.68; 95% CI 0.54 to 0.84) but not pulmonary (OR 0.50; 95% CI 0.19 to 1.29) or all-cause (OR 0.96; 95% CI 0.63 to 1.47) mortality compared with placebo and ipratropium. Reductions in exacerbations and hospitalisations compared with LABA were not statistically significant. Similar patterns were evident for quality of life and symptom scales. Tiotropium yielded greater increases in forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) from baseline to 6-12 months than did placebo, ipratropium, and LABA. Decline in FEV1 over 1 year was 30 ml (95% CI 7 to 53) slower with tiotropium than with placebo and ipratropium (data were not available for LABA). Reports of dry mouth and urinary tract infections were increased with tiotropium.

Conclusions: Tiotropium reduced COPD exacerbations and related hospitalisations, improved quality of life and symptoms, and may have slowed the decline in FEV1. Long term trials are warranted to evaluate the effects of tiotropium on decline in FEV1 and to clarify its role compared with LABA.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr Barr: none. Dr Bourbeau has received honoraria for CME, membership on advisory boards and financial support from government agencies, contract and investigator initiated research studies for a number of companies including Altana, Astra Zeneca, Bayer, Boehringer‐Ingelheim, GlaxoSmithKline, Novartis and Pfizer. Dr Camargo has received investigator initiated grants and consulting/lecture honoraria from AstraZeneca, Boehringer‐Ingelheim, GlaxoSmithKline, and Novartis. Dr Ram: none.

References

    1. Murray C J L, Lopez A D. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 19973491498–1504. - PubMed
    1. Haddad E, Mak J, Barnes P. Characterization of 3H Ba 679 BR, a slowly dissociation muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol Pharmacol 199445899–907. - PubMed
    1. Disse B, Speck G A, Rominger K L.et al Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 199964457–464. - PubMed
    1. Barnes P J. The pharmacological properties of tiotropium. Chest 2000117(2 Suppl)63–6S. - PubMed
    1. Barr R G, Bourbeau J, Camargo C A., Jret al Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews, 2005; Issue 2 - PMC - PubMed

Publication types

MeSH terms